教員業績データベース |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. |
掲載誌名 | 正式名:European journal of nuclear medicine and molecular imaging ISSNコード:16197089/16197070 |
掲載区分 | 国外 |
巻・号・頁 | 50(5),pp.1487-98 |
著者・共著者 | Kitajima Kazuhiro, Igeta Masataka, Kuyama Junpei, Kawahara Takashi, Suga Tsuyoshi, Otani Tomoaki, Sugawara Shigeyasu, Kono Yumiko, Tamaki Yukihisa, Seko-Nitta Ayumi, Ishiwata Yoshinobu, Ito Kimiteru, Toriihara Akira, Watanabe Shiro, Hosono Makoto, Miyake Hideaki, Yamamoto Shingo, Narita Mitsuhiro, Daimon Takashi, Yamakado Koichiro |
発行年月 | 2023/04 |
概要 | PURPOSE: To develop a novel nomogram for determining radium-223 dichloride (Ra-223) treatment suitability for metastatic castration-resistant prostate cancer (mCRPC) patients. METHODS: This Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial was a retrospective multicenter investigation enrolled 258 mCRPC patients in Japan with Ra-223 treatment between June 2016 and August 2020, with bone scintigraphy findings before treatment, clinical data, and survival outcome available. A nomogram was constructed using prognostic factors for overall survival (OS) based on a least absolute shrinkage and selection operator Cox regression model. A sub-analysis was also conducted for patients meeting European Medicines Agency (EMA) guidelines. |
PMID | 36539508 |